Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949554 | 0.90 | KMT2A (0.39) | NCF1KMT2AALDH1A1CYP2C9SLC9A1 | |
| SCHEMBL13744845 | 0.85 | KMT2A (0.45) | KMT2AALDH1A1CYP1A2CYP2C9MAPT | |
| SCHEMBL8430270 | 0.84 | ALDH1A1 (0.46) | KMT2AALDH1A1CYP1A2MAPTPOLB | |
| SCHEMBL584259 | 0.81 | GNAI3 (0.51) | KMT2AALDH1A1CYP1A2CYP2C9SLC9A1 | |
| SCHEMBL3401956 | 0.81 | NCF1 (0.45) | NCF1ALDH1A1TPSAB1TPSD1TPSG1 | |
| SCHEMBL14611310 | 0.81 | ALDH1A1 (0.43) | KMT2AALDH1A1CYP1A2RAB9ACYP3A4 | |
| SCHEMBL14393798 | 0.81 | GNAI3 (0.47) | KMT2AALDH1A1CYP1A2POLB | |
| SCHEMBL14949559 | 0.80 | ALDH1A1 (0.43) | KMT2AALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL22732655 | 0.80 | ALDH1A1 (0.43) | KMT2AALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL22732628 | 0.80 | ALDH1A1 (0.43) | KMT2AALDH1A1MAPTPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| CN-117820292-A | Quinazolinone derivatives, preparation method and application thereof | 合肥医工医药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116199686-A | Trifluoromethyl substituted sulfonamide compounds | 正大天晴药业集团股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-112888687-B | Trifluoromethyl substituted sulfonamides selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-112888687-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020238785-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2019185025-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | NCF1 2229/4885KMT2A 1814/4885ALDH1A1 2458/4885 |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | BCL2L11, BCL2, BCL2L1 | NCF1 1643/4885KMT2A 414/4885ALDH1A1 3369/4885 |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | BCL2L11, BCL2, BCL2L2 | NCF1 2229/4885KMT2A 1814/4885ALDH1A1 2458/4885 |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2, BAX, BCL2L2 | NCF1 2059/4885KMT2A 1415/4885ALDH1A1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.